Clinical trial
Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone…
NCT00407251 · British Columbia Cancer Agency, Other · Completed
Key facts
| NCT number | NCT00407251 |
|---|---|
| Title | Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy |
| Official title | A Phase II Study of Patupilone (EPO906A) as a Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer |
| Lead sponsor | British Columbia Cancer Agency, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hormone Refractory Prostate Cancer |
| Intervention type | Drug |
| Interventions | Patupilone |
| Enrollment | 73 |
| Start date | Feb 1, 2007 |
| Primary completion | Jun 1, 2010 |
| First posted | Dec 4, 2006 |
| Last update posted | Nov 5, 2010 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: